drugset
drugset / Trial / NCT00167219

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

NCT00167219 ↗

Phase 1/2 Completed 15 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).

Timeline

Start
1999-11-18
Primary completion
2022-07-12
Completion
2023-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-MERCAPTOETHANESULFONIC ACID Small molecule — —
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic — —
Subject Busulfan Small molecule — Other
Subject Cyclophosphamide Other / unclassified — Other
Subject Melphalan Small molecule — Other

Indications

juvenile myelomonocytic leukemia